Sensitivity to transforming growth factor-b is impaired in thyroid tumours. Similar to Mad -Mother Against Decapentaplegic-(Smad)4 is frequently altered in cancers, but its involvement in this system is unknown. We analysed 56 thyroid tumours of various histotypes for Smad4 mutations by PCR-SSCP and sequencing, linking them to Smad4 reactivity as examined by immunohistochemistry (IHC), and 29 of them also for abnormalities in RNA expression due to alternative splicing. In all, 15/56 cases (27%), both benign and malignant lesions, harbour alterations of Smad4 coding sequence. We found several novel intragenic mutations (13 missense, two silent, one frameshift and one large insertion-deletion), with high incidence in the linker region. A subset of mutated tumours failed to express Smad4 protein by IHC. We have also detected four alternatively spliced tumourassociated Smad4 isoforms, lacking portions of the linker region, and three more due to unreported internal exonexon rearrangements. Smad4 is both frequently mutated and deregulated by aberrant splicing in thyroid tumours and these alterations may contribute as an early event to thyroid tumorigenesis.
Introduction
Transforming growth factor-b (TGF-b) is involved in morphogenesis, differentiation and cell growth control. It binds to type I (TbRI/ALK5) and type II (TbRII) cell membrane receptors starting cytoplasm signalling through their serine-threonine kinase activity. A large body of evidence indicates that the Similar to MadMother Against Decapentaplegic-(Smad) family proteins account for most of the TGF-b signalling downstream the membrane. Upon receptor-induced association in active complexes and subsequent nuclear translocation, Smads join to other transcription factors, select distinct DNA target sequences and finely tune the spectrum of TGF-b actions (Shi and Massague´, 2003; ten Dijke and Hill, 2004) .
Destruction of the TGF-b signalling network at the level of Smad genes is common in human carcinomas. Several sporadic epithelial tumours, in fact, show missense, nonsense and frameshift Smad4 point mutations (Miyaki and Kuroki, 2003; Iacobuzio-Donahue et al., 2004) as like as homozygous deletions at Smad4 locus (Takakura et al., 1999; Blaker et al., 2002; Maru et al., 2004) . Likewise, germline mutations occur in a group of juvenile polyposis syndrome (JPS) affected subjects (Howe et al., 1998) . Smad proteins show a tripartite structural organization, and three main domains have been recognized: Mad homology 1 (MH1), Mad homology 2 (MH2) and an interposed linker region (Shi 2001) . Mutations affecting MH2 region may either (i) disrupt the protein folding by interfering with the maintenance of the b-sandwich structure, (ii) prevent the formation of Smad2-Smad4 heterodimer by altering some residues located both in the loop/helix region and the three-helix bundle relevant for intermolecular interactions, or (iii) alter the L3 loop, equally affecting interactions with receptor-activated Smads (Shi et al., 1997) . Mutations in the MH1 domain reduce Smad-4 DNA-binding ability and nuclear translocation of the complex (Jones and Kern, 2000) . A very low number of abnormalities has been found until now in the linker region (exons 3-7) (Shi et al., 1997) , in spite of the fact that it includes Smad activation domain (SAD) motif (aa 274-321) (Shi, 2001) .
In thyroid cell lines the differentiated phenotype is controlled by TGF-b, which inhibits iodide trapping and thyreoglobulin synthesis (Colletta et al., 1989) , and some of these effects are exerted through Smad signalling (Nicolussi et al., 2003; Costamagna et al., 2004) . TGF-b is also the main negative regulator of thyreocyte proliferation: it antagonizes the mitogenic effects of the main growth factors (Colletta et al., 1989) and delays progression during the mid-late G 1 phase (Carneiro et al., 1998; Depoortere et al., 2000) .
Escape from TGF-b action is actively selected during thyroid tumour development. Thyroid cell lines, chronically exposed to TGF-b action in culture, develop TGFb-resistant clones (Coppa et al., 1995) . Moreover, expression of TbRII at both RNA and protein level is reduced in more than 80% of thyroid carcinomas, especially of the papillary type . A lower TbRII expression has been demonstrated in KRas transformed rat thyroid cell lines, and re-expressing TbRII significantly reduced malignant properties of these cells in vitro (Coppa et al., 1997) and in nude mice models (Turco et al., 1999) . On the contrary, involvement of Smad pathways in thyroid tumours has not been deeply investigated yet. This work studies Smad4 status in a representative group of sporadic thyroid neoplasms, through mutational analysis and study of expression of alternatively spliced isoforms. We show that Smad4 is mutated at high frequency and also aberrantly spliced in tumours, which induces to consider Smad4 as an important target of alterations during thyroid tumorigenesis.
Results

Smad4 is frequently mutated
A total of 56 thyroid tumours of different histopathology (12 of them with matched lymph node metastases), all paired to normal tissues, were subjected to polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) mutational analysis on the entire Smad4 coding sequence. In all, 16 abnormal alleles were revealed in 15 tumours (#20 had two of them in exons 2 and 7). As shown in Figures 1 and 2 , the abnormal alleles coexist with the wild-type ones in 13/15 cases, whereas #41 and #7A (both with exon 7 alterations) lack normal alleles. In all, 19 different mutations were discovered from sequencing the 16 extra bands, as summarized in Table 1 . A total of 17 mutations are intragenic, whereas two are located in intron sequences, one (#37) at 5 0 of exon 3 and the other (#3) þ 26 nucleotides away from the stop codon of exon 11. Out of 17 coding mutations, 13 are missense and introduce a different amino-acid residue, two are silent, one (#39) is a one base insertion in exon 7 at codon 303 (a C between nt 907 and 908) with a frameshift and a predicted stop codon 12 bases downstream (codon 307), and the last one (#41) is a large deletion-insertion in exon 7. Seven tumours harbour one mutation, four cases are mutated twice: in particular, samples #28I, #2A and #20 harbour two missense, while case #36 has one missense and one silent mutation. In three out of these four cases (#28I, #2A and #36) both mutations have been sequenced from the same cloned abnormal PCR-SSCP band, indicating they lay on the same Smad4 allele. This statement cannot be verified for sample #20, because mutations were detected on separately amplified exons (V128M on exon 2, I314N on exon 7). All Smad4 mutated sequences are depicted in Figures 1 and 2 , under their respective SSCP banding patterns. The intragenic missense mutations target the MH1, linker and MH2 regions in 1/15 (6.5%), 7/15 (46.5%) and 7/15 (46.5%) cases, respectively ( Figure 3 ). All these Smad4 mutations found in this study are novel: targeted codons have not been reported so far as mutational spots, with partial exception of His317 (#6A), already found changed to arginine (and not glutamine as here) in an ovarian cancer (Takakura et al., 1999) . Thus, a relevant fraction of thyroid tumours (27%) harbour somatic Smad4 gene abnormalities: such a mutation frequency is comparable to that of sporadic gastrointestinal tumours (somatic mutations) (Hahn et al., 1998; Blaker et al., 2002; Miyaki and Kuroki, 2003; Iacobuzio-Donahue et al., 2004) and of JPS cases (germline mutations) (Howe et al., 1998) .
Smad4 is alternatively spliced RNA from 37 neoplastic samples and from 21 paired normal tissues have been subjected to RT-PCR (Retrotranscribed-PCR) for alternate transcript analysis. Fulllength Smad4 cDNA, 1659 bp long, was then internally reamplified with primers spanning the linker region and several extra bands, beside the expected standard 918 bp fragment, have been identified. Table 2 summarizes the number and percentage of cases that presented alternatively spliced Smad4 variants, while a comprehensive scheme of all of them is shown in Figure 4 . A more abundant 682 bp splicing form (DEx5-6), previously described in primary neuroblastoma (Kageyama et al., 1998) , in the MDA-MB231 mammary (de Winter et al., 1997) and HaCaT human keratinocyte (Pierreux et al., 2000) cell lines, occurs in more than 65% of both tumour and normal samples. An additional DEx4-6 variant (468 bp), also previously reported (Kageyama et al., 1998) , has been observed in 7/37 tumours and in 3/21 normal tissues. In contrast, all of the other spliced isoforms are tumour-associated and represented only once. We report for the first time the presence of DEx6 (801 bp) and DEx4-7 (417 bp) variants in vivo, described so far at low amount only in HaCaT cells (Pierreux et al., 2000) . Notably, DEx4-7 form, lacking almost the entire linker region, is the only transcript detected in papillary thyroid carcinoma (PTC) #41, which bears the wide deletion-insertion excluding the exon 7. Moreover, we characterize three new splicing events due to internal exon-exon rearrangements, a phenomenon never described before for Smad4 gene. Two involve repeated sequences: Dcod95-293, between CTATGCC at np 282-288 and np [878] [879] [880] [881] [882] [883] [884] , between GCATC at np 568-572 and np 721-725, which uncovers a cryptic splice site between flanking GT and AG motives. The third one, Dcod117-373, is not rearranged between common sequences. Dcod95-293 and Dcod117-373 introduce frameshifts at the joining, with stop codons downstream, while Dcod190-240 misses parts of exons 4 and 5 but remains in frame and may generate a novel protein product. With the exception of DEx5-6 Figure 1 Mutations of Smad4 gene in thyroid tumours at exons 2, 4, 7 and 9. Panels a show SSCP runs including the abnormal alleles of the different exons. The white asterisks (*) indicate the additional bands which contained the mutations. Number and histology of the different samples are reported above each panel: HA is for Hu¨rthle cell adenoma, FA for follicular adenoma, PTC for papillary thyroid carcinoma. T indicates that the amplified product is from tumour, N from normal tissue, respectively. In some cases normal tissue has been sampled from two different areas of the gland (N1 and N2). Panels b show comparatively the sequences of the part of the exon including the mutation from tumour samples (T) and the wild-type sequences from the normal counterparts (N). Arrows (5 0 m or 5 0 k) sign reading directions; the nuleotide triplets where mutations fall and the amino-acid changes are also indicated. The sequences are from cloned bands and show only the mutated allele, with exception of HA#20 and FA#6A at exon 7, which have been sequenced directly from PCR product, and thus both alleles are present in DNA from the tumour sample. Sequence of PTC#41, extensively rearranged at exon 7, is not reported Smad4 is mutated and abnormally spliced in thyroid tumours D Lazzereschi et al variant, all forms appear to be preferentially associated with PTC, with an overall frequency of 64% (9/14). DEx4-6 isoform, in fact, is also present in four PTC, and DEx6, DEx4-7, Dcod117-373 and Dcod95-293 variants are all owned by PTC; interestingly, the sample #37, harbouring in frame Dcod190-240 cDNA, is an adenomatous hyperplasia (AH) with a focal PTC area inside. An agarose gel with representative RT-PCR of Smad4 exon 2-9 fragments and sequences of the extraband splice junctions is depicted in Figure 5 .
Immunohistochemical (IHC) characterization of Smad4 mutated tumours
IHC data in Table 3 summarize Smad4 protein expression and distribution in 12/13 samples with and HTC #2A) show diffuse Smad4 positivity, to be explained as no effect of mutations on Smad4 protein stability and expression level or as a result of compensation by the residual wild-type allele. FA #50 presents a peculiar pattern of weak scattered immunoreactivity in all tumour cells, both in their cytoplasm and nuclei (Figure 6h ), compared to the usual diffuse reactivity of the adjacent normal thyroid tissue, maybe related to its S432G mutation. We have extended the IHC analysis also to the samples without Smad4 mutations, and Smad4 expression appeared to be retained in all, with the exception of two other PTC, which displayed Smad4-negative areas.
Discussion
The present work analyses for the first time the mutational and the expression status of Smad4 in a consistent number of thyroid tumours of different histotypes. Our data show a high frequency of Smad4 abnormalities: over a total of 56 samples considered, 15 cases (27%) harbour one or more alterations in the Smad4 coding sequence: only tumours arising from the gastrointestinal tract, both sporadic and inherited, are known to display a comparable Smad4 mutation frequency (Iacobuzio-Donahue et al., 2004) . Few of the Smad4 mutations in thyroid tumours are frameshift or nonsense mutations (2/15 cases) and Smad4 homozygous deletions have not been detected in our study, unlike pancreatic and colorectal cancers (Moore et al., 2001; Miyaki and Kuroki, 2003; Iacobuzio-Donahue et al., 2004) . Four tumours harbour two Smad4 mutations, that in three cases result to be located on the same allele: the occurrence of two Smad4 mutations on a same exon or allele has already been described (Blaker et al., 2002; Miyaki and Kuroki, 2003; IacobuzioDonahue et al., 2004) . Mutations do not correlate with specific pathologic aspects: frequencies, in fact, are similar for the different histotypes, ranging from 40% in HA to 21% in PTC (Table 3) , whereas tumour subtypes have been preferentially linked to Smad4 alterations in pancreatic and appendiceal cancers (Moore et al., 2001; Maru et al., 2004) and JPS cases (Gallione et al., 2004) . The presence of Smad4 mutations in both benign (5/12) and malignant (7/12) thyroid tumours suggests that this is an early event, as proposed in colorectal cancers (Woodford-Richens et al., 2001a, b) . This study does not support the presence of mutational hotspots (IacobuzioDonahue et al., 2004), because our mutations scattered all along the Smad4 sequence. Nevertheless, besides the H317Q mutation, which affects the same codon of H317R (Takakura et al., 1999) , five other missense mutations (V128M, M331T, F339S, S432G, H496R) are placed adjacent to the elsewhere described changes N129K (Koyama et al., 1999) , P130S (Thiagalingam et al., 1996) , E330A (Takagi et al., 1996; Ohtaki et al., 2001) , D332G (Yakicier et al., 1999) , K340E (Takagi et al., 1996) , A433V (Ohtaki et al., 2001) Alternative splicing is a tool to increase the number and diversity of proteins expressed by eukaryotic cells. The link between human inherited diseases or cancers and abnormal alternative splicing has been recently strengthened (Ca`ceres and Kornblitt, 2002) . Relaxation of mRNA splice control in thyroid seems a relatively frequent event, and a number of genes involved in thyroid differentiation, such as thyreoglobulin, phosphodiesterase-8B (Pde8B), and thyreoperoxidase, or tumorigenesis, that is c-Ret and CD44, show abnormal splicing events (Bertaux et al., 1991; Ermak et al., 1996; Fluge et al., 2001; Hayashi et al., 2002; Ferrand et al., 2003) . We demonstrate the presence of a number of alternatively spliced Smad4 forms, all lacking variable portions of the linker region, namely DEx6, DEx5-6, DEx4-6 and DEx4-7. It has been demonstrated that such variants are unable to resume the transcriptional activity of TGF-b when expressed in Smad4-null cell lines (Pierreux et al., 2000) . Deletions of the SAD domain, which encompasses the most of exon 6 and the entire exon 7, have a dominant-negative effect on normal TGF-b-dependent signalling and regulated transcription (Pierreux et al., 2000; Shi, 2001) , probably because this domain includes the region of interaction with Smif coactivator protein (residues 275-308) (Bai et al., 2002) . Three new rearrangements outside the classic boundaries have also been discovered, two of which are due to recombination of internal repeated sequences: in one case a new in-frame product is generated, lacking 50 residues between exons 4 and 5. Significantly, such uncommon aberrant splicing events between internal repeated sequences have been already detected just in thyroid carcinomas in charge of Pde8B (Hayashi et al., 2002) and CD44 (Ermak et al., 1996) Figure 3 Distribution of Smad4 mutations found in the present study with respect to Smad4 domains and exons; * and 1 symbols indicate mutations held by the same case. Nonsense mutation is located where the stop codon occurs Loss of Smad4 immunoreactivity would be expected for mutations affecting protein stability and/or expression level. IHC revealed that Smad4 protein is not expressed in a subset of our mutated tumours: accordingly, these mutations are located in motives (A226T and N263S in the linker region, C324Y, S432G and P550S in MH2 domain) affecting Smad4 stability when changed (Shi et al., 1997; Shi, 2001 ). This statement is supported by IHC of PTC metastasis #11.8, C324Y mutated, largely Smad4 negative (Figure 6f ), compared to the matched primary thyroid tumour and to other synchronous metastases, all diffusely Smad4 positive (Figure 6b) . Conversely, other mutations may result in Smad4 functional impairment by interference with association to its partners, even with a dominantnegative action. For instance, the mutations I314N (case #20), H317Q (case #6A), placed in the SAD domain (Shi, 2001 ) and R496H (case #49) -altering an important ionic link with Asp493 of the Smad2/3 counterparts (Shi et al., 1997) -may all disturb the formation of homo-and/or heteromeric Smad complexes, but have no consequence on IHC pattern. In thyroid tumours, similarly to other cancers (Moore et al., 2001; Iacobuzio-Donahue et al., 2004) , IHC results do not mirror mutational Smad4 status.
The mutations described in this study do not disturb the immunoreactivity of Smad4 protein with the antiserum used, which recognized a main epitope codified by exon 5 (Woodford-Richens et al., 2001b), with partial exception of the sample #28, whose A226T change falls in the same exon. In conclusion, the present study strongly implicates Smad4 alterations in thyroid tumorigenesis, resulting from a multifaceted pattern of molecular abnormalities. The potential impairment of TGF-b signalling at Smad4 level may constitute an early and frequent event in thyroid tumours natural history. Our data confer further relevance to the statement that escaping from TGF-b control is almost an obligate requirement in thyreocyte multistep transformation process.
Materials and methods
Tissue samples
In all, 56 thyroid tumours of different histopathology and variable clinical behaviour were collected at surgery after informed consent at the University of Rome 'La Sapienza' in the years from 1996 to 2001. They include 4 AH, 11 FA, 5 HA, 28 PTC, 4 FTC, 2 HTC and 2 ATC (Anaplastic Thyroid Carcinoma). In PTC #28 a second neoplastic intrathyroid lesion, localized in the isthmic portion, has been sampled as #28I. Moreover, we have included in the study lymph node metastases from 12/28 PTC cases. Snap-frozen tumour and matched normal tissue samples were used for DNA and RNA studies, sampling with special care to avoid contamination between normal and tumour tissues, while routinely processed, paraffin-embedded, material was retrieved for IHC. Diagnosis has been performed by one of the author (FN) according to WHO criteria.
DNA extraction and SSCP analysis
Tumour and normal tissues from 56 samples were powdered, homogenized in DNA extraction buffer, treated with 400 mg/ ml proteinase K and phenol-chloroform extracted (Lazzereschi et al., 1997). The entire Smad4 coding sequence (11 exons, including intron-exon boundaries) has been screened by SSCP analysis after PCR amplification with intronic primers specific for individual exons, except for exons 5 and 6, which were co-amplified. Primers were taken from Kim et al. (1996) , but pairs for exons 1, 2, 3, 4 and 11 were redrawn as follows: exon 1, primer S, 5 0 -CAAAGGATCAAAATTGCTTCAG-3 0 , primer AS, 5 0 -GAGTATGTGAAGAGATGGAG-3 0 ; exon 2, primer S, 5 0 -TGTATGACATGCCAAGTTAG-3 0 , primer AS, 5 0 -CAATACTCGGTTTTAGCAGTC-3 0 ; exon 3, primer S, 5 0 -GCGTTTATGCTACTTCTGAATTG-3 0 , primer AS, 5 0 -GCCCCTAACCTCAAAATCTAC-3 0 ; exon 4, primer S, 5 0 -CTTTTGCTGGTAAAGTAGTATG-3 0 , primer AS, 5 0 -CTCAACTTGCTGACTACATCT-3 0 ; exon 11, primer S, 5 0 -GTCCCTCTGATGTCTTCC-3 0 , primer AS, 5 0 -ATTGT ATTTTGTAGTCCACC-3 0 . Genomic DNAs, 0.1 mg each, were amplified for 35 cycles in a reaction mix containing 1 Â 32 P]dCTP (10 mCi/ml, 370 MBq/ml, Amersham Pharmacia Biotech, Uppsala, Sweden), according to a standard PCR protocol with denaturation at 941C for 30 s, variable annealing temperature for 1 min and elongation at 721C for 1 min 30 s. Negative controls without DNA were run in parallel. PCR products from tumour and normal tissues were run aside onto MDE gels (Cambrex Bioscience Rockland Inc., Rockland, ME, USA) under nondenaturing conditions at 41C for 5 h. Vacuum-dried gels were subjected to autoradiography. Abnormally migrating DNA fragments were cut away and purified. PCR-SSCP analyses were repeated three times for each sample and migration patterns interpreted by two independent investigators.
RNA extraction and nested RT-PCR
For RNA extraction, 29 (6 FA, 1 AH with a little PTC area, 4 HA, 14 PTC, 2 FTC, 2 ATC) tumours, 7 PTC lymph node metastases, 1 secondary intrathyroid PTC localization and 21 paired normal tissues, snap-frozen at collection, were powdered, homogenized in 4.0 M guanidinium thiocyanate, 25 mM sodium citrate, pH 7.0, 0.5% sarcosyl and 0.1 M 2b-mercaptoethanol. Total RNA has been isolated using the guanidinium thiocyanate acid-phenol-chloroform extraction method, as described previously . Extracted RNA was checked by fractionation on 1% formaldehyde agarose gels. Total RNA, 4 mg each, was retrotranscribed for 1 h at 421C using Superscript II RNAse H À reverse transcriptase (200 U) with 10 mM dNTP and 1 : 1 v/v Random Hexamer/ OligodT 12-18 mix (all from GIBCOt Invitrogen Corp.), according to the manufacturer's instructions. The cDNA obtained represents bona fide the entire tissue RNA array from each tumour and normal sample. One-tenth of the reaction volume has then been amplified for 40 cycles to obtain full-length Smad4 cDNA using the following primer set: P1, primer S, 5 0 -AAGGATCAAAATTGCTTCAGA-3 0 , and P3, primer AS, 5 0 -CAGTCTAAAGGTTGTGGGTC-3 0 , with denaturation at 941C for 30 s, annealing at 581C for 1 min 30 s and elongation at 721C for 2 min 30 s, in a PCR reaction driven by r-Tth TaqXL DNA polymerase (Perkin-Elmer-Applied Biosystems). The 1720 bp amplification product includes the entire wild-type Smad4 cDNA, 1658 bp long. The amplified product, diluted 1 : 500, has been subjected to a second step of 'nested PCR' using three pairs of partially overlapping primers, one spanning the region from the 5 0 -UTR to the beginning of exon 2, the second from exon 2 to the beginning of exon 9, the third from the 3 0 of exon 8 to the proximal part of the 3 0 -UTR. Only the second pair of primers (primer S, ns-S1, 5 0 -GGTCGGAAAGGATTTCC-3 0 and primer AS, N-8AS, 5 0 -CCAACTGCACACCTTTGCCTA-3 0 ) has identified the presence of extra bands beside the standard fragment of 918 bp. Amplification products were resolved on ethidium bromide-stained, 2% agarose gels: bands resulting from abnormal splicing events were cut and purified using the QIAquick gel extraction kit (Qiagen Inc., Valencia, CA, USA).
DNA mutation and RNA splicing variants cloning and sequencing
Abnormal PCR and RT-PCR products have been cloned into the PCR 2.1-TOPO s vector with TOPO-TA s cloning system, according to the manufacturer's instructions (GIBCOt Invitrogen Corp.). Only in cases #20 and #6A, exon 7 mutants have been directly sequenced from the amplified DNA. All samples have been manually sequenced with the ddNTP termination method using incorporation of a[
35 S]dATP and the Sequenase II sequencing kit (both from Amersham Pharmacia Biotech) and resolved at room temperature on prewarmed 6% polyacrylamide gels with variable running times. Vacuumdried gels were subjected to autoradiography. Sequencing has been performed on the sense and antisense strands with M13 forward (À20 sited) and reverse primers, specific for TOPO s cloning vector, and with primers for the individual Smad4 exons, including the following: ex5Seq S, 5 0 -TGAAATCAT AAGATGACATCTATGAATG-3 0 ; ex6Seq AS, 5 0 -TTACA AGAGCTTACAGTAATGTC-3 0 ; ex7Seq S, 5 0 -TAGTAAAT AAAAATGGAATTTTGT-3 0 ; ex7Seq AS, 5 0 -CAATCTAAA TACAGGAAATCAAT-3 0 ; ex8Seq S, 5 0 -TGTTGTGGAGTG CAAGTGAAAG-3 0 ; ex9Seq AS, 5 0 -TTTTGACAACAAATA GAGCTTTAAGTC-3 0 . Sequence data were always confirmed twice using independent DNA preparations.
IHC analysis
IHC for Smad4 has been performed on paraffin-embedded 5-mm thick sections from routinely processed tissues, as previously described . Normal goat serum has been used to block nonspecific sites (Vector, Burlingame, CA, USA). Slides were then incubated in a humidified chamber overnight at 41C with 1 : 100 dilution of polyclonal serum to Smad4 (H-552, Santa Cruz Biotechnology Ltd, Santa Cruz, CA, USA). The peroxidase-based LSAB2 Detection kit (DAKO A/S, Glostrup, Denmark), followed by haematoxylin counterstaining, has been used to visualize the reactions. Control sections were processed by substituting the primary antibody with a normal rabbit IgG fraction (DAKO), and all showed no colour reactions. Specificity of Smad4 staining in thyroid malignancies was confirmed by staining serial sections for HBME and galectin-3, diffusely positive in all tumour areas.
